Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications

Arthritis Research & Therapy 2013, 15:R73 doi:10.1186/ar4250

Valerie Gagne (valerie.gagne@crchul.ulaval.ca)
Louis Marois (louis.marois@crchul.ulaval.ca)
Jean-Michel Levesque (jean.michel.levesque@hotmail.com)
Hugo Galarneau (hugo.galarneau@crchul.ulaval.ca)
Mireille H Lahoud (lahoud@burnet.edu.au)
Irina Caminschi (caminschi@burnet.edu.au)
Paul H Naccache (Paul.Naccache@crchul.ulaval.ca)
Philippe Tessier (philippe.tessier@crchul.ulaval.ca)
Maria JG Fernandes (maria.fernandes@crchul.ulaval.ca)

ISSN 1478-6354
Article type Research article
Submission date 6 October 2012
Acceptance date 21 June 2013
Publication date 9 July 2013
Article URL http://arthritis-research.com/content/15/4/R73

This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in Arthritis Research & Therapy are listed in PubMed and archived at PubMed Central.

For information about publishing your research in Arthritis Research & Therapy go to

http://arthritis-research.com/authors/instructions/

© 2013 Gagne et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Modulation of Monosodium Urate Crystal-induced Responses in Neutrophils by the Myeloid Inhibitory C-type Lectin-like Receptor: Potential Therapeutic Implications

Valérie Gagné¹, Louis Marois¹, Jean-Michel Levesque¹, Hugo Galarneau¹, Mireille H Lahoud², Irina Caminschi², Paul H Naccache¹, Philippe Tessier¹ and Maria JG Fernandes¹.

¹ Department of Microbiology-Infectiology and Immunology, Faculty of Medicine, Laval University Centre de recherche en rhumatologie et immunologie, Centre de recherche du CHUQ-CHUL, Bloc TI-49, 2705 boulevard Laurier, Québec, Québec, G1V 4G2, Canada.

² Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3050, Australia.

VG and LM contributed equally to this work.

Corresponding author:
Maria JG Fernandes
Abstract

Introduction: Monosodium urate crystals (MSU), the etiological agent of gout, are one of the most potent pro-inflammatory stimuli for neutrophils. The modulation of MSU-induced neutrophil activation by inhibitory receptors remains poorly characterized. The expression of the myeloid inhibitory C-type lectin-like receptor (MICL) in neutrophils is downregulated by several pro-inflammatory stimuli suggestive of a role for this receptor in neutrophil function. We thus investigated the potential role of MICL in MSU-induced neutrophil activation.

Methods: The expression of MICL was monitored in human neutrophils by flow cytometry and Western blot analysis after stimulation with MSU. Protein tyrosine phosphorylation was also assessed by Western blot analysis and the production of IL-1 and IL-8 by enzyme-linked immunosorbent assay. Changes in the concentration of cytoplasmic-free calcium were monitored with the Fura-2/AM calcium indicator. MICL expression was modulated with an anti-MICL antibody in neutrophils and siRNA in the PLB-985 neutrophil-like cell line.

Results: MSU induced the downregulation of MICL expression in neutrophils. A diminution in the expression of MICL induced by antibody-cross linking or siRNA enhanced the MSU-dependent increase in cytoplasmic calcium levels, protein tyrosine phosphorylation and IL-8 but not IL-1 production. Pre-treatment of neutrophils with colchicine inhibited the MSU-induced downregulation of MICL expression.

Conclusions: Our findings strongly suggest that MICL acts as an inhibitory receptor in human neutrophils since the downregulation of MICL expression enhances MSU-induced neutrophil activation. Since MSU downregulate the expression of MICL, MICL may play a pathogenic role in gout by enhancing neutrophil effector functions. In support of this notion, colchicine counteracts the MSU-induced loss of MICL expression. Our findings thus also provide further insight into the potential molecular mechanisms behind the anti-inflammatory properties of this drug.

Key words: Gout, neutrophil, immunoreceptor tyrosine-based inhibitory motif, monosodium urate crystals, cytokine production, signalling.
Introduction

Gout is one of the most painful types of arthritis and its prevalence is on the rise worldwide [1, 2]. The inflammatory reaction typical of an acute gout attack is initiated by the crystallized form of a by-product of purine metabolism, monosodium urate crystals (MSU). A gout attack can be viewed in three phases, the initiation, effector and subsequent resolution phase. According to the current understanding of the pathogenesis of acute gout, MSU activate resident articular cells (e.g: macrophages) during the initiation phase most commonly in the metatarsophalangeal joint [3]. The activation of resident cells by MSU induces the synthesis of several inflammatory mediators including active interleukin-1β (IL-1β), a cytokine that plays a pivotal role in the pathogenesis of gout implicating the NLRP3 inflammasome in this inflammatory disorder. IL-1β contributes to the initiation and perpetuation of the effector phase by virtue of its ability to stimulate endothelial cells of the vasculature to express potent chemokines (eg: IL-8) and adhesion molecules responsible for the massive recruitment of neutrophils to the joint.

The recruitment of a large number of neutrophils to the affected joint during the effector phase is the pathological hallmark of gouty arthritis [4]. The presence of activated phagocytes in the joint is one of the main causes of tissue destruction and pain in gout. When activated by MSU, neutrophils release a panoply of inflammatory molecules including cytokines (eg: IL-1β, IL-8, S100) and degradative enzymes that perpetuate the inflammatory reaction as well as oxygen radicals that cause damage to the surrounding tissues (recently reviewed in [4]). At the molecular level, the signalling molecules driving MSU-induced neutrophil responses are just beginning to be identified, they include activated Src-family kinases (eg: Lyn), Syk, PKC, PI-3K and Tec [4]. Since the activation of Src-kinases is an early signalling event, the majority of MSU-induced effector functions depend on these kinases.

Animal studies and clinical observations underscore the pivotal role of the neutrophil in gout. A significant decrease in MSU-induced inflammation was reported in neutropenic mice. Moreover, medications used to treat gout such as colchicine, downregulate MSU-induced neutrophil effector functions [4]. It is thus of interest to characterize molecular mechanisms that regulate MSU-induced neutrophil activation.

Leukocyte activation is regulated, in part, by phosphatases that block early signalling events of activating receptors when recruited to the plasma membrane. Phosphatase recruitment occurs via immunoreceptor tyrosine-based inhibitory motifs (ITIM) located in the cytoplasmic portion of inhibitory receptors expressed on the surface of leukocytes [5]. Inhibitory receptors can be classified into two main groups on the basis of their structure, namely, the immunoglobulin or the C-type lectin superfamily. Proteins of the latter contain at least one C-type lectin-like domain (CTLD). Myeloid inhibitory C-type lectin receptors are poorly characterized in comparison to their counterparts in NK cells (recently reviewed in [6]). Findings from the few myeloid inhibitory receptors studied suggest, however, that these proteins are able to suppress several phagocyte effector functions including phagocytosis, migration and cytokine production [7].

The myeloid inhibitory C-type lectin-like receptor (MICL) is a type II transmembrane protein comprising 1 CTLD in its extracellular domain and an ITIM in its cytoplasmic domain [8-12]. It is expressed by monocytes, macrophages, neutrophils, myeloid and plasmacytoid dendritic cells. The natural ligand(s) of human MICL remains to be identified. Although unequivocal evidence for a negative regulatory function of MICL is still lacking in the published literature, the majority of evidence suggests that MICL does indeed have inhibitory activity. The recruitment of the phosphatases SHP-1 and SHP-2 to the ITIM of MICL was observed in a macrophage cell line [8]. Moreover, in response to a variety of TLR ligands, the cell-surface expression of MICL diminishes in human monocytes and macrophages suggestive of a negative regulatory role for this receptor [9]. Supporting this hypothesis, the cell-surface expression of MICL was shown to be diminished in neutrophils recruited to a site of inflammation using an abrasion model of the skin in human volunteers [9]. The antibody-induced internalization of MICL in monocyte-derived dendritic cells showed, however, that
the loss of cell-surface MICL can either positively or negatively regulate cytokine production. The internalization of MICL prior to stimulation with LPS suppresses the production of IL-12p40 and IL-12p70 [10]. In contrast, the internalization of MICL prior to stimulation with CD40 ligand enhances the production of TNF-α, IL-12p40, IL-12p70, IL-6 and IL-10 [10]. A role for MICL in antibody responses has also been reported. Targeting antigen to MICL can induce antibody responses [13].

Since MICL regulates the synthesis of cytokines in dendritic cells and its expression is modulated by pro-inflammatory stimuli, the objective of this study was to investigate the role of MICL in MSU-induced activation of neutrophils and to determine whether MSU modulate MICL expression. Herein, we report for the first time that MSU diminish MICL expression in human neutrophils. A decrease in MICL expression in neutrophils selectively enhances MSU-induced cytokine release by neutrophils and also potentiates early signalling events. We also provide direct evidence that colchicine inhibits the MSU-induced loss of cell-surface MICL suggesting that the regulation of MICL expression may be a new mechanism through which this drug dampens inflammation.
Methods

Antibodies and chemicals

Two different antibodies against MICL were used in this study. Monoclonal antibodies 50C1 and HB3 were kindly provided by Dr M. Lahoud [13] and by Dr G. Brown [8], respectively. These antibodies recognize extracellular epitopes of MICL. FITC-conjugated F(ab’)2 goat anti-human F(ab’)2 fragment specific (no. 115-096-097) was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Horseradish peroxidase-labelled sheep anti-mouse IgGs (no. NXA931) were obtained from GE Healthcare (Uppsala, Sweden). The anti-phosphotyrosine (clone 4G10, no. 05-321) and the anti-p85 (no. 06-195) antibodies were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Monoclonal anti-Flotillin-1 antibody (no. 610820) was purchased from BD Transduction Laboratories (Mississauga, ON, Canada). The mouse IgG2a isotype antibody (no.0572) was purchased from Beckman Coulter (Mississauga, ON, Canada). Anti-CD11b antibody (OKM1, no.88012702) was purchased from Sigma-Aldrich Canada (Oakville, ON, Canada) and the anti-FPRL1 antibody was obtained from R&D Systems (Mineapolis, MN, USA). Sodium orthovanadate (Na3VO4), N,2'-O-dibutyryladenosine-3',5'-cyclic monophosphate sodium salt (dibutyryl cAMP), colchicine and Dextran T-500 were obtained from Sigma-Aldrich Canada (Oakville, ON, Canada). CHAPS, Aprotinin and leupeptin were purchased from Roche Applied Science (Laval, QC, Canada). Western lightning chemiluminescence plus was obtained from Perkin Elmer (Boston, MA, USA). Ficoll-Paque and Hepes were obtained from Wisent (St-Bruno, QC, Canada). Protein A-Sepharose was purchased from GE Healthcare. Gelatin was obtained from Fisher (Nepean, ON, Canada). Fura-2-AM was obtained from Invitrogen and the triclinic MSU crystals were synthesized and characterized as previously described in Naccache et al [14]. Endotoxin contamination was ruled out by Limulus amebocyte lysate assay. The siGENOME SMARTpool MICL (no. D-021369-01) and siGENOME non-targeting siRNA pool #1 (negative control, no. D-001206-13-05) were purchased from Dharmacon Inc (Lafayette, CO, USA).

Cells

The Institutional Review Board of the Université Laval (Québec, QC, Canada) approved the study, and volunteers signed a consent form. Neutrophils were collected from healthy adult volunteers and isolated as previously described [15]. They were resuspended in Mg2+-free HBSS containing 1.6 mM of CaCl2. The myeloid cell line PLB-985 was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and grown in RPMI 1640 medium containing 10% decomplemented FBS, 10mM Hepes, 1 mM Na-pyruvate at 37°C in a 5% CO2 humidified atmosphere. The cells were maintained in culture for 12 passages before new batches were thawed. To induce differentiation to a neutrophil-like phenotype, PLB-985 cells were cultured in medium supplemented with 0.3 mM dibutyryl cAMP for 3 days prior to each experiment.

Transfection of db-cAMP-differentiated PLB-985 cells

One day following the initiation of differentiation with 0.3 mM dibutyryl cAMP, PLB-985 cells were transiently transfected using the Nucleofector system from Amaza Biosystems. Briefly, 2 × 106 cells were centrifuged and resuspended in 100 µl of nucleofection buffer (25 mM Hepes pH 7.4, 120 mM KCl, 2 mM MgCl2, 10 mM K2HPO4, 5 mM L-cysteine) containing 3 µg of MICL-specific siRNA (siMICL) or negative control siRNA (siCtrl). The samples were transferred into an electroporation cuvette, and transfections performed with the program setting U-002. After nucleofection, cells were immediately transferred into pre-warmed complete RPMI 1640 medium containing 0.3 mM dibutyryl cAMP, 10% FBS, 10 mM Hepes, 1 mM Na-pyruvate and maintained at 37°C in a 5% CO2 humidified atmosphere. Two days after nucleofection, cells were harvested and resuspended in Mg2+-free HBSS containing 1.6 mM CaCl2 for analysis.
Flow cytometry analysis

To monitor the plasma membrane expression of MICL on neutrophils stimulated with different agonists, neutrophils were transferred to tubes cooled in an ice bath to terminate the stimulations and centrifuged at 400 × g for 2 min at 4°C. The cell pellets were then resuspended in buffer with 50C1 (1 µg/ml) or the IgG2a isotype control antibody and incubated for 30 min on ice, washed, centrifuged and the resuspended cell pellets incubated for a further 30 min on ice with FITC-labelled goat anti-mouse Fcγ specific IgG (diluted 1/100 in HBSS/BSA). Cells were then washed twice in HBSS/BSA and analysed by flow cytometry with BD FACSCanto II flow cytometer from BD Biosciences (San Jose, CA, USA). To monitor the antibody-induced internalization of cell-surface MICL, freshly isolated neutrophils were incubated with 50C1 antibody (1 µg/ml) or IgG2a isotype antibodies for the indicated times at 37°C, washed and the resuspended cell pellets incubated for a further 30 min on ice with FITC-labelled goat anti-mouse Fcγ specific IgG (diluted 1/100 in HBSS/BSA). In some experiments, neutrophils were treated with 10µM colchicine or diluent (DMSO) for 30 min at 37°C and centrifuged to wash away the drug prior to stimulating with 1 mg/ml MSU for 20 min at 37°C.

Trichloroacetic acid (TCA) protein precipitation

Human neutrophils (20×10⁶ cells/ml) were stimulated with MSU crystals (1 µg/ml) at 37°C, quickly centrifuged and supernatants precipitated with 15% trichloroacetic acid for 30 min at 4°C. Samples were then centrifuged at 16 000×g for 5 min and washed three times with acetone. Pellets were dried at 95°C for 2 min and resuspended in modified Laemmli’s buffer.

Enzyme-linked immunosorbent assay (ELISA)

The assessment of the extracellular IL-8 was performed using commercially available ELISA kits (Human IL-8 cytoset, no. CHC1303) from Invitrogen (Burlington, ON, Canada). All samples were measured in duplicate. Briefly, cAMP-differentiated PLB-985 cells were stimulated for 3 hr at 37°C with 1 mg/ml MSU crystals in RPMI 1640, centrifuged (5 min, 16 000 ×g) and the supernatants harvested and filtered. Extracellular IL-8 was quantified with commercially available ELISA kits (BD Bioscience). All samples were measured in triplicate. For the quantitation of extracellular IL-1β, neutrophils primed with TNF-α or incubated in buffer were stimulated for 8 hr with MSU at 37°C and IL-1β quantified in the cell-free supernatant with a commercially available ELISA kit from eBioscience (SanDiego, CA; catalog no. 88-7010-22). All samples were measured in duplicate. To determine the effect of colchicine on the MSU-induced production of IL-8, neutrophils were treated with 10µM colchicine or diluent (DMSO) for 30 min at 37°C prior to adding MSU (1 mg/ml) or buffer to the neutrophil-colchicine mixture and incubating it for a further 3 hours at 37°C. It is of note that the effect of colchicine on neutrophils is reversible (data not shown). For colchicine to be effective, it should not be removed from the neutrophil suspension for the duration of the experiment for assays longer than 20 minutes.

Electrophoresis and immunoblotting

For Western blot analysis, cell suspensions were transferred directly into the same volume of 2X boiling modified Laemmli’s sample buffer (1X buffer: 62.5 mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 5% (v/v) β-mercaptoethanol, 8.5% (v/v) glycerol, 2.5 mM orthovanadate, 10 µg/ml leupeptin, 10 µg/ml aprotinin and 0.025% bromophenol blue) to terminate cell activation with MSU, and boiled for 7 min. Proteins were separated by SDS-PAGE on 10% acrylamide gels under non-reducing conditions and transferred to PVDF membranes. Blocking agents and antibodies were diluted in a TBS-Tween solution (25 mM Tris-HCl, pH 7.8, 190 mM NaCl, 0.15% v/v Tween 20). PVDF membranes were incubated in blocking solution (5% w/v dried milk in TBS-Tween) prior to immunoblotting with the anti-MICL (HB3 antibody) or anti-Flotillin-1 antibodies. Gelatin solution (2% w/v) was used as a
blocking solution prior to immunoblotting with the anti-phosphotyrosine (4G10) antibody. Anti-MICL and anti-Flotillin antibodies were diluted 1:1000 and anti-phosphotyrosine antibodies was diluted 1:2000. Horseradish peroxidase-labeled sheep anti-mouse IgGs was diluted 1:20,000 in TBS-Tween solution. Chemiluminescence reagents were used to detect antibodies, with a maximal exposure time of 5 min. All the immunoblots presented were controlled for equal protein loading with an anti-p85 of PI3K antibody.

Calcium mobilization
Neutrophils ($10^7$ cells/ml) were incubated for 30 min at 37°C with 1 µM Fura-2/AM, washed once in HBSS, resuspended to a concentration of $5 \times 10^6$ cells/ml and transferred to a temperature controlled (37°C) cuvette compartment of a spectrofluorimeter (SLM 8000, Aminco, Urbana, IL). Cell-associated fluorescence was monitored at an excitation wavelength of 340 nm and an emission wavelength of 510 nm. The internal calcium concentrations were calculated as described by Grynkiewicz et al [16].

Statistical analysis
Statistical analyses were performed using the Student paired t test (two-tailed) with GraphPad Prism4 Software on the raw data. Significance was considered to be attained at a value of $p < 0.05$. 

Results

MSU crystals reduce MICL expression in human neutrophils

The modulation of the cell-surface expression of MICL by a variety of TLR agonists in human monocytes, macrophages and monocyte-derived dendritic cells as well as mouse neutrophils prompted us to determine whether MICL expression is downregulated by pro-inflammatory stimuli, in this case, MSU. The cell-surface expression of MICL was monitored by flow cytometry in human neutrophils stimulated up to 20 min with 1mg/ml MSU (Figure 1A). After one minute of stimulation, the level of expression of cell-surface MICL remained unchanged. In contrast, a significant reduction in the expression of MICL was observed after 20 min of stimulation with MSU. For comparative purposes, the modulation of the cell-surface expression of MICL by soluble agonists was also examined. None of the agonists tested, TNF-α, GM-CSF, G-CSF, PAF, the TLR4 ligand LPS as well as the TLR1 and TLR2 ligand pam3csk4 (data not shown) modulated MICL plasma membrane expression. Similarly, we detected no change in the surface expression of MICL in response to the particulate stimulus, non-opsonized zymosan (Figure 1B). MSU is thus the only stimulus tested that can directly induce the internalization of cell-surface MICL. To determine whether the internalization of MICL observed with the above stimuli could be induced with the anti-MICL antibody (clone 50C1), neutrophils were incubated with 50C1 antibody and internalization assessed by flow cytometry with a fluorochrome-conjugated secondary antibody as described in Methods. We show that 50C1 can induce the internalization of cell-surface MICL in human neutrophils (Figure 1C).

We then asked whether the change in cell-surface MICL was accompanied by the degradation of the receptor. To test this hypothesis, an aliquot of the human neutrophil suspension (cell pellet and supernatant) stimulated with MSU was lysed and analyzed by Western blot with an anti-MICL antibody. A significant decrease in the amount of total MICL was observed (Figure 2A & B). Since the lysate analyzed represents extracellular and intracellular MICL, these results indicate that the fate of the MICL receptor after its internalization is its degradation. Analysis of the cell pellet and supernatant separately supported this interpretation of our observations since MICL was not detectable in the supernatant of MSU-activated neutrophils (Figure 2C). Stimulation of neutrophils with MSU thus not only induces the downregulation of the expression of cell-surface MICL but also its degradation.

MICL negatively regulates the production of IL-8 by MSU-activated human neutrophils

To determine the functional significance of the downregulation of MICL expression by MSU, we next examined the effect of the silencing of MICL expression on MSU-induced cytokine production since MICL is known to modulate the synthesis of cytokines by monocyte-derived dendritic cells. The refractory nature of neutrophils to transfection prompted us to use PLB-985 cells that acquire a neutrophil-like phenotype upon differentiation with dibutyryl cAMP [17-19]. Upon differentiation, PLB-985 cells increase the expression cell-surface expression of MAC-1 (Figure 3A & [20]) and FLPR1 (Figure 3A). Moreover, both published and our unpublished observations reveal that the response of this cell line to MSU crystals is similar to that of human neutrophils [19].

To verify that the expression of MICL can be knocked-down in PLB-985 cells, the cells were transfected with control siRNA or MICL siRNA and the cell-surface expression of MICL determined by flow cytometry. MICL siRNA significantly diminishes the cell-surface expression of MICL (p=0.021) (Figure 3B). Moreover, the silencing MICL expression has no effect on the differentiation of PLB-985 cells. The level of expression of MAC-1 and FLPR1 is the same in differentiated cells transfected with the control or MICL siRNA (data not shown).

Having demonstrated that MICL expression can be silenced by MICL-specific siRNA in neutrophil-like PLB-985 cells, we then examined how the diminution in MICL expression affects MSU-induced IL-8 production. The amount of IL-8 measured in the cell-free supernatant of MSU activated, cAMP-
differentiated PLB-985 silenced for MICL expression was significantly superior in comparison to cells transfected with control siRNA (Figure 3C). To confirm this observation in human neutrophils, the internalization of cell-surface MICL was induced with the 50C1 antibody prior to stimulation with MSU as in Figure 1C. Neutrophils incubated with 50C1 prior to stimulation with MSU produced significantly larger amounts of IL-8 in the cell-free supernatant (Figure 3D) than those treated with an isotype antibody (IgG2a). Thus, using two different experimental strategies, we provide evidence that a reduction in the cell-surface expression of MICL potentiates MSU-induced IL-8 production in neutrophils.

The production of IL-1 by MSU-activated human neutrophils is not regulated by MICL

Having demonstrated the modulation of the MSU-induced release of IL-8 by human neutrophils, we next examined the possibility that MICL may regulate the production of IL-1β since this cytokine is reported to play a pivotal role in gout. The MSU-induced synthesis of IL-1β by macrophages, cells that produce this cytokine during the initiation phase of gout, is well documented. In contrast, the production of IL-1β by MSU-stimulated neutrophils remains poorly characterized. We thus examined the ability of neutrophils to synthesize and release IL-1β in response to MSU. As shown in Figure 4, neutrophils stimulated with MSU do not release detectable amounts of IL-1β. This may be explained by the fact that the synthesis of this cytokine is a multistep process involving the synthesis of pro-IL-1β and its subsequent inflammasome-mediated maturation. IL-1β synthesis requires two signals. The first signal is thought to modulate the threshold of the inflammasome and the second, to activate the inflammasome-dependent maturation of pro-IL-1β. Indeed, the stimulation of neutrophils with MSU after TNF-α priming induces the release of a significant amount of IL-1β in the cell-free supernatant. A similar amount of IL-1β was measured in the cell-free supernatant of TNF-α–primed neutrophils stimulated with MSU after the 50C1-induced internalization of MICL. Together, the above observations indicate that MICL does not regulate the production of IL-1β in neutrophils stimulated with MSU.

The diminution of MICL expression enhances MSU-induced signalling in human neutrophils

Having observed a modulation of IL-8 production by MICL, we next asked whether MICL modulates signalling pathways activated by MSU. We chose to focus on the modulation of MSU-induced tyrosine phosphorylation of intracellular proteins since ITIM-bearing receptors are notorious for regulating early signalling events. Tyrosine phosphorylation of intracellular substrates was visualized by Western blot analysis using an anti-phosphotyrosine antibody. The series of bands shown in the blot in Figure 5, represents the distinct tyrosine phosphorylation profile induced in neutrophils by MSU and is consistent with that previously described [21]. A rapid and transient increase in the tyrosine phosphorylation of intracellular substrates was observed within a minute after stimulation of neutrophils with MSU (Figure 5). Maximum tyrosine phosphorylation was observed at approximately 1-2 min following MSU stimulation and began to diminish by 5 min. Even though a similar kinetics in the tyrosine phosphorylation of intracellular substrates was observed in neutrophils stimulated with MSU after 50C1 engagement, the intensity of the tyrosine phosphorylation profile was much higher in these cells in comparison to that of neutrophils stimulated with MSU alone. As a control, we show that 50C1 alone does not induce an intense tyrosine phosphorylation profile of intracellular substrates.

Another early signalling event is the increase in the intracellular levels of cytoplasmic-free calcium. We provide evidence that the 50C1-induced diminution of the expression of cell-surface MICL significantly enhanced the MSU-induced increase in cytoplasmic-free calcium (Figure 6).

Together, the above findings are suggestive of a negative regulatory role for MICL since a decrease in its cell-surface expression enhances two of the earliest signalling events in neutrophils upon
stimulation with MSU, the tyrosine phosphorylation of intracellular proteins and an increase in intracellular levels of cytoplasmic-free calcium.

**Colchicine reduces the internalization of MICL on human neutrophils**

The modulation by MICL of various neutrophil responses towards MSU led us to hypothesize that anti-inflammatory drugs may dampen inflammation by targeting MICL. Our working hypothesis is that MICL negatively regulates MSU-induced neutrophil responses since a decrease in its expression enhances the effector functions of neutrophils towards MSU. Since colchicine is very effective in inhibiting a variety of MSU-induced neutrophil effector functions, some of which are modulated by MICL including calcium mobilization and tyrosine phosphorylation, the effect of this anti-inflammatory drug on the MSU-induced internalization of MICL was examined. The addition of colchicine to resting neutrophils did not affect the expression of MICL as determined by flow cytometry. In contrast, the MSU-induced internalization of MICL was significantly retarded in colchicine pre-treated neutrophils (Figure 7). This effect of colchicine on MICL internalization is specific for the MSU-induced internalization of MICL since colchicine was not able to retard the 50C1-induced loss of MICL cell-surface expression. Together, these observations strongly suggest that the anti-inflammatory properties of colchicine may be partially explained by the ability of this drug to preserve the expression of MICL on the surface of human neutrophils.

**Colchicine inhibits the production of IL-8 by MSU-activated human neutrophils**

Colchicine is known to inhibit all the MSU-induced neutrophil responses modulated by MICL. The effect of the alkaloid on the production of IL-8 has, however, not been examined as of yet. Its effect on the production of this cytokine in response to MSU was thus determined. Neutrophils incubated with colchicine produced significantly lower amounts of IL-8 when activated with MSU than neutrophils stimulated with MSU in the absence of the drug (Figure 8). This finding supports the notion that colchicine inhibits IL-8 production by neutrophils stimulated with MSU, in part, through MICL since colchicine favors the retention of this inhibitory receptor on the cell surface precluding the full activation of the neutrophil.
Discussion

Inhibitory receptors are essential for the maintenance of immune homeostasis by abrogating signalling pathways that lead to cellular activation [5]. Even though inhibitory receptors may contribute to the pathogenesis of inflammatory diseases by virtue of their ability to modulate leukocyte activation, little is known about their roles in disease. This is the first report of the modulation of the expression of an inhibitory receptor by the etiological agent of gout. The activation of human neutrophils with MSU results in the loss of MICL expression. The functional significance of the diminution of MICL expression is an enhancement in the MSU-induced release of IL-8. This finding is of clinical relevance since IL-8 is a potent neutrophil chemoattractant. The loss of MICL expression may thus be a requisite for the recruitment and/or perpetuation of neutrophil-driven gout flares. Moreover, we also show that an inflammatory drug used to treat gout, colchicine, inhibits the effect of MSU on MICL expression.

Our observation that MSU downregulates MICL expression adds to a growing list of pro-inflammatory stimuli that diminish the cell-surface expression of MICL in neutrophils. MSU is the first damage-associated molecular pattern demonstrated to modulate MICL expression. The biological significance of the negative modulation of MICL expression in neutrophils by pro-inflammatory stimuli other than MSU (mostly TLR agonists) remains largely unexplored rendering the interpretation of these results challenging. One report has, however, investigated the functional effect of the diminution of cell-surface MICL on cytokine synthesis in monocyte-derived dendritic cells [10]. In this report, Chen et al. demonstrate that a diminution in the expression of cell-surface MICL inhibited or augmented cytokine production in a stimulus-dependent manner. In response to LPS, the production of TNF-α, IL-12p40 and IL-12p70 was suppressed upon MICL internalization. In contrast, the production of TNF-α, IL-12p40, IL-12p70, IL-6 and IL-10 was enhanced in response to CD40 ligand. Since inhibitory receptors can dampen cellular activation or in some cases activate the cells, it remains unclear whether MICL is an inhibitory receptor. We used a siRNA approach to resolve this issue. Our demonstration that the silencing of MICL expression significantly enhances the release of IL-8 by MSU-activated neutrophils strongly supports the notion that MICL acts as an inhibitory receptor in human neutrophils.

The modulation of IL-8 production by MICL in neutrophils is of relevance to gout. The massive recruitment of neutrophils to the inflamed joint is a pathological hallmark of gout, and this recruitment is reduced in mice deficient in CXCR2. It is thus reasonable to propose that the MSU-induced downregulation of MICL expression releases the inhibitory activity of this receptor in neutrophils permitting the activation of the neutrophil by this non-microbial agent. Interestingly, MICL does not regulate the MSU-induced production of IL-1β. The molecular mechanisms underlying the selective nature of MICL regulation of the production of cytokines by MSU-activated neutrophils remain to be identified. Whether MICL modulates the release of other chemotactic factors or cytokines by neutrophils remains to be determined. With regards to the ability of MICL to modulate additional MSU-induced neutrophil responses, we did not observe any modulation of MSU-induced degranulation or 5-LO production in human neutrophils subsequent to the antibody-induced internalization of MICL (data not shown). These observations suggest that MICL modulates a subset of molecular pathways employed by MSU to activate human neutrophils.

At the molecular level, we show that MICL modulates early MSU-induced signalling events in neutrophils. The stimulation of neutrophils with MSU induced the loss of cell-surface MICL leading to the enhancement of the MSU-induced increase in the concentration of intracellular calcium and tyrosine phosphorylation of intracellular substrates. These observations corroborate the observed enhancement in MSU-induced IL-8 production upon the downregulation of MICL expression. Both MSU-induced tyrosine phosphorylation and IL-8 production depend on the activation of Src-kinases in neutrophils. The inhibition by MICL of MSU-induced early signalling events is consistent with the
known mode of action of inhibitory receptors and is strongly suggestive that MICL may regulate several MSU-induced neutrophil effector functions driven by downstream signalling events.

Neutrophils pre-treated with colchicine internalize significantly less cell-surface MICL in the presence of MSU. This observation provides additional evidence for the ability of MICL to negatively regulate the MSU-induced activation of neutrophils. We propose that colchicine preserves the cell-surface expression and consequently the inhibitory activity of MICL shifting the balance between pro- and anti-inflammatory signals towards the latter. It thus follows that MSU may induce tyrosine phosphorylation of intracellular substrates and the mobilization of intracellular calcium, in part, by internalizing MICL since these neutrophil responses are enhanced subsequent to the antibody-induced internalization of MICL and inhibited by colchicine. Regarding the MSU-induced secretion of IL-8, the ability of colchicine to inhibit this neutrophil response to MSU remains unexplored. We thus investigated the effect of colchicine on the production of this cytokine in response to MSU. Colchicine downregulates the MSU-induced release of IL-8 in human neutrophils (Figure 8). Together, these observations strongly suggest that MICL regulates very early signalling events involving Src-kinases, since MSU-induced tyrosine phosphorylation of intracellular substrates as well as the increases in the concentrations of free cytosolic calcium and the production of IL-8 are all Src-tyrosine kinase-dependent events. MICL is the first inhibitory pathway identified that could partly explain the anti-phlogistic activity of colchicine. Since colchicine destabilizes microtubules by binding alpha and beta monomers of tubulin, it is not unreasonable to suggest that MICL interacts directly or indirectly with the microtubule network.

A limitation of our experimental approach is that the internalization of MICL was induced prior to MSU stimulation to investigate the effect of MICL on MSU-induced responses. Although this approach is widely used to investigate inhibitory receptors whose ligands remain unidentified, it remains to be determined whether cells expressing a mutant form of MICL that is resistant to MSU-induced internalization/degradation respond more weakly to MSU.

As mentioned above, MSU is the first damage-associated molecular pattern shown to modulate MICL expression and consequentially its function. The regulation of MICL expression by damage-associated molecular patterns may differ from that of pathogen-associated molecular patterns and other pro-inflammatory stimuli. Indeed, MSU is the only stimulus that we studied that modulates MICL expression in resting neutrophils. Moreover, studies that previously published the diminution of cell-surface MICL by stimuli other than damage-associated molecular patterns were performed on primed neutrophils. We show, however, that in resting neutrophils, MICL expression is not modulated by pro-inflammatory stimuli that are not damage-associated molecular patterns. Together, these observations indicate that neutrophils have to receive two stimuli/signals prior to mobilizing cell-surface MICL when activated with non-damage-associated molecular pattern stimuli. In contrast, damage-associated molecular patterns seem to be able to override the necessity of a primary signal (neutrophil priming) and affect MICL expression directly.

Conclusion

In summary, our findings strongly suggest that MICL may play a pathogenic role in gout by being one of the targets of MSU. We propose that MSU downregulate the inhibitory activity of MICL by diminishing its expression resulting in the full activation of human neutrophils. In contrast, colchicine has the opposite effect on the cell-surface expression of MICL. MICL is thus a potential therapeutic target for gout. Further characterization of the role of MICL in MSU-induced neutrophil activation and the molecular events driving MICL function is necessary to shed light onto the pathogenic role of MICL in gout and its potential as a drug target. Since neutrophils are the principal players in the inflammatory flares typical of gout, it is not unreasonable to suggest that MICL may also play a similar pathogenic role in other chronic diseases characterized by recurrent, neutrophil-driven inflammatory
episodes such as rheumatoid arthritis. It is thus of interest to gain further insight into the potential role of MICL in the effector phase of these chronic inflammatory diseases.

**Abbreviations**
- C-type lectin-like domain (CTLD), control siRNA (siCtrl), immunoreceptor tyrosine-based inhibitory motifs (ITIM), MICL-specific siRNA (siMICL), monosodium urate crystals (MSU), myeloid inhibitory C-type lectin-like receptor (MICL), N,2’-O-dibutyryladenosine-3’,5’-cyclic monophosphate sodium salt (dibutyryl cAMP).

**Competing interests**
'The author(s) declare that they have no competing interests'

**Acknowledgements**
The authors wish to thank Dr. Alexandre Brunet for expert technical assistance in flow cytometry analysis. We also wish to thank Myriam Vaillancourt for her technical assistance in IL-8 ELISA analysis. This research was funded by operating funds awarded to MJGF by the Canadian Arthritis Network (CAN), the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Crohn’s and Colitis Foundation of Canada (CCFC). LM is a recipient of the Canadian Arthritis Network post-doctoral award and VG received a Ph.D. scholarship from Fonds de recherche Québec-Santé and the CCFC. MJGF is a recipient of the Arthritis Society Investigator Award.

**Authors’ contributions**
VG, LM, JML and HG performed the experiments, analyzed and interpreted the data. LM also participated in the writing of the manuscript and revised it for intellectual content. MJFG conceived the project, participated in its design and coordination and drafted and revised the manuscript. MHL, IC, PHN and PT contributed to the design of the project and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
References

1. Martinon F: Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 2010, 233:218-232.
2. Weaver AL: Epidemiology of gout. Cleve Clin J Med 2008, 75 Suppl 5:S9-12.
3. Busso N, So A: Mechanisms of inflammation in gout. Arthritis Res Ther 2010, 12:206.
4. Popa-Nita O, Naccache PH: Crystal-induced neutrophil activation. Immunol Cell Biol 2010, 88:32-40.
5. Daeron M, Jaeger S, Du Pasquier L, Vivier E: Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008, 224:11-43.
6. Pyz E, Marshall AS, Gordon S, Brown GD: C-type lectin-like receptors on myeloid cells. Ann Med 2006, 38:242-251.
7. Steevels TA, Meyaard L: Immune inhibitory receptors: essential regulators of phagocyte function. Eur J Immunol 2011, 41:575-587.
8. Marshall AS, Willment JA, Lin HH, Williams DL, Gordon S, Brown GD: Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem 2004, 279:14792-14802.
9. Chen CH, Floyd H, Olson NE, Magaletti D, Li C, Draves K, Clark EA: Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood 2006, 107:1459-1467.
10. Han Y, Zhang M, Li N, Chen T, Zhang Y, Wan T, Cao X: KLRL1, a novel killer cell lectinlike receptor, inhibits natural killer cell cytotoxicity. Blood 2004, 104:2858-2866.
11. Bakker AB, van den Oudенrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA, Marissen WE, Radošević K, Throsby M, Schuurhuis GJ, Ossenkoppele GJ, de Kruijff J, Goudsmit J, Kruisbeek AM: C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004, 64:8443-8450.
12. Lahoud MH, Proietto AI, Ahmet F, Kitsoulis S, Eidsmo L, Wu L, Sathe P, Pietersz S, Chang HW, Walker ID, Maraskovsky E. Braley H, Lew AM, Wright MD, Heath WR, Shortman K, Caminschi I: The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol 2009, 182:7587-7594.
13. Naccache PH, Grimard M, Roberge CJ, Gilbert C, Lussier A, Demedicis R, Poubelle PE: Crystal-Induced Neutrophil Activation 1. Initiation and Modulation of Calcium Mobilization and Superoxide Production by Microcrystals. Arthritis and Rheumatism 1991, 34:333-342.
14. Fernandes MJ, Lachance G, Pare G, Rollet-Labelle E, Naccache PH: Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases. J Leukoc Biol 2005, 78:524-532.
15. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca^{2+} indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260:3440-3450.
18. Marois L, Vaillancourt M, Pare G, Gagne V, Fernandes MJ, Rollet-Labelle E, Naccache PH: CIN85 modulates the down-regulation of Fc gammaRIIa expression and function by c-Cbl in a PKC-dependent manner in human neutrophils. *J Biol Chem* 2011, 286:15073-15084.

19. Popa-Nita O, Marois L, Pare G, Naccache PH: Crystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase Tec. *Arthritis Rheum* 2008, 58:1866-1876.

20. Pivot-Pajot C, Chouinard FC, El Azreq MA, Harbour D, Bourgoin SG: Characterisation of degranulation and phagocytic capacity of a human neutrophilic cellular model, PLB-985 cells. *Immunobiology* 2010, 215:38-52.

21. Roberge CJ, Gaudry M, de Medicis R, Lussier A, Poubelle PE, Naccache PH: Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. *J Clin Invest* 1993, 92:1722-1729.
Figure legends:

**Figure 1: Surface MICL expression is significantly decreased upon activation of human neutrophils with MSU**
The plasma membrane expression of MICL was examined by flow cytometry on freshly isolated neutrophils (10×10⁶ cells/ml) after incubation at 37°C with (A) MSU (1 mg/ml) for 20 min, (B) non-opsonized zymosan (z) (ratio 10 z/cell), LPS (22.5 ng/ml in 1X HBSS containing 5% decomplemented FBS), TNF-α (100 U/ml), GM-CSF (80 nM), G-CSF (50 ng/ml) or PAF (10⁻⁶ M) for 15 min or (C) the 50C1 antibody (1 µg/ml) or IgG2a isotype control antibody for 5 min or 20 min as described in Methods. MICL expression was compared to the control. The raw, flow cytometry data in (A) is shown in the right panel. These graphs are compilations of four independent experiments.

**Figure 2: Total MICL expression is reduced upon activation of human neutrophils with MSU**
(A) Freshly isolated human neutrophils (20×10⁶ cells/ml) were incubated with MSU (1 mg/ml) at 37°C and the stimulation terminated. Aliquots of suspension were stopped at 20 min by transferring directly in the same volume of non-reducing 2X boiling modified Laemmli’s sample buffer. Whole-cell lysates were probed in Western blot for MICL (anti-MICL clone HB3, upper panel) and PI3K-p85 (lower panel) as loading control. This result is representative of eight independent experiments. (B) Densitometric ratios of (A) are represented on the graph. (C) Human neutrophils (20×10⁶ cells/ml) were incubated with MSU (1 mg/ml) at 37°C. Aliquots of suspension were centrifuged and pellets were stopped at the indicated times in non-reducing 2X boiling modified Laemmli’s sample buffer. Supernatant were precipitated with 2,2,2-trichloroacetic acid (TCA) as described in Methods. Pellets and supernatants were probed in Western blot for MICL (anti-MICL clone HB3). This result is representative of tree independent experiments.

**Figure 3: MICL modulates MSU-induced IL-8 secretion in human neutrophils**
PLB-985 cell line was differentiated with dibutyryl cAMP for 72 hr as described in Methods. The plasma membrane expression of MAC-1 (OKM1), the fMLP receptor (FPRL1) and MICL were analyzed by flow cytometry on differentiated and undifferentiated PLB-985 cells. IgG2b and IgG2a were used as control isotypes. (B) Dibutyryl cAMP-differentiated, neutrophil-like PLB-985 (20 × 10⁶ cells/ml) were transfected by Amaxa nucleofection system with a MICL-specific siRNA (siMICL) or with a negative control siRNA (siCtrl). Cells were then stimulated for 3 hr at 37°C with 1 mg/ml MSU crystals in RPMI 1640. Cells were centrifuged (5 min, 16,000 ×g) and the supernatants were harvested and filtered. Extracellular IL-8 was quantitated with commercially available ELISA kits. All samples were measured in duplicate. This graph is a compilation of four independent experiments. (C) MICL surface expression was monitored by flow cytometry following siRNA transfections. Cells (10×10⁶ cells/ml) were incubated with 50C1 antibody (2 µg/ml) for 30 min on ice, washed and incubated with FITC-labelled goat anti-mouse Fcγ specific IgG (diluted 1/100 in HBSS/BSA) for 30 min on ice. Cells were then washed twice in HBSS/BSA and analysed by flow cytometry with BD FACSCanto II flow cytometer from BD Biosciences. This graph is a compilation of four independent experiments. (D) Human neutrophils (20 × 10⁶ cells/ml) were incubated with anti-MICL antibody (clone 50C1, 2 µg/ml) or IgG2a isotype for 5 min at 37°C and washed. Cells were then stimulated with MSU crystals at 1 mg/ml or not for 3 hr at 37°C. Extracellular IL-8 was monitored as described in (B). All samples were measured in triplicate. This result is a compilation of five independent experiments.
Figure 4: MICL does not modulate MSU-induced IL-β production in primed, human neutrophils
Resting human neutrophils (20 x 10^6 cells/ml) or neutrophils incubated with the IgG2a isotype antibody, 50C1 in the presence or absence of TNF-α were stimulated with MSU crystals (1 mg/ml) for 8 hr at 37°C, centrifuged and IL-1β quantified in the cell-free supernatant by ELISA as described in Methods. All samples were measured in duplicate. This graph is a compilation of four independent experiments.

Figure 5: MICL modulates MSU-induced tyrosine phosphorylation pattern in human neutrophils
Human neutrophils (20x10^6 cells/ml) were pre-incubated with anti-MICL antibody (clone 50C1, 2 µg/ml) (+) or IgG2a isotype (-) for 5 min and washed. Cells were then stimulated with MSU (1 mg/ml) at 37°C. Aliquots of the cell suspension were stopped at the indicated times by transferring directly into the same volume of 2X boiling modified Laemmli’s sample buffer. Whole-cell lysates were probed by Western blot for tyrosine phosphorylation (clone 4G10, upper panel) and Flotillin-1 (lower panel), the loading control. This result is representative of three independent experiments.

Figure 6: MICL modulates MSU-induced calcium mobilization in human neutrophils
(A) Human neutrophils (10x10^6 cells/ml) were pre-incubated with Fura-2 AM (1 µM) for 30 min at 37°C. The extracellular probe was removed by washing in HBSS, and the cells were resuspended at (5x10^6 cells/ml). Anti-MICL antibody (clone 50C1, 2 µg/ml) or IgG2a isotype was added for 5 min. Cells were transferred a thermostat-controlled (37°C) cuvette compartment of a spectrofluorimeter (SLM 8000, Aminco, Urbana, Ill). Calcium mobilization was measured following the addition of 1 mg/ml MSU crystals at 37°C. Fluorescence was monitored at an excitation wavelength of 340 nm and an emission wavelength of 510 nm. The internal calcium concentrations were calculated as described in [16]. This result is representative of four independent experiments.

Figure 7: Colchicine inhibits the MSU-induced internalization of MICL in human neutrophils
Freshly isolated human neutrophils were treated with colchicine (10µM) (+) or DMSO (-) for 30 min at 37°C and then incubated with (A) MSU (1 mg/ml) for 20 min at 37°C or with (B) 50C1 for 5 min at 37°C. The stimulations were terminated by transferring the tubes to an ice bath followed by centrifugation at 400 x g for 2 min at 4°C. The cell pellets were washed in cold HBSS containing 0.005% BSA and incubated with (A) 50C1 for 30 min followed by incubation with FITC-labelled goat anti-mouse Fcγ specific IgG (diluted 1/100 in HBSS/BSA) for 30 min on ice or with (B) FITC-labelled goat anti-mouse Fcγ specific IgG (diluted 1/100 in HBSS/BSA) for 30 min on ice. Cells were then washed twice in HBSS/BSA and analysed by flow cytometry with BD FACSCanto II flow cytometer from BD Biosciences (San Jose, CA, USA).This graph is a compilation of 7 independent experiments in (A) and 3 independent experiments in (B).

Figure 8: Colchicine modulates MSU-induced IL-8 secretion in human neutrophils
Neutrophils were incubated in colchicine (10µM) (+) or DMSO (-) for 30 min at 37°C prior to adding MSU (1 mg/ml) or buffer to the neutrophil-colchicine mixture and incubating it for a further 3 hours at 37°C. The quantity of IL-8 in the supernatant was determined by ELISA. A compilation of data of three independent experiments is shown (N=3).
**Figure 1**

A. Bar graph showing the effect of MSU (1mg/ml) on MICL surface expression over time. The x-axis represents time (min) with values 0 and 20, and the y-axis represents MICL surface expression (ratio of control). The data shows a significant increase in MICL expression at 20 min compared to 0 min with an asterisk indicating statistical significance (***p=0.0003).

B. Bar graph showing the effect of various stimuli on MICL surface expression. The x-axis represents different stimuli: -, Z, LPS, TNF, GM-CSF, G-CSF, and PAF, while the y-axis represents MICL surface expression (ratio of control). The data shows a slight increase in MICL expression for most stimuli, with the exception of Z, which shows a decrease.

C. Bar graph showing the effect of incubation time on MICL surface expression. The x-axis represents incubation time (min) with values 5 and 20, and the y-axis represents MICL surface expression (ratio of control). The data shows a significant increase in MICL expression at 20 min compared to 5 min with asterisks indicating statistical significance (*p=0.0417 and *p=0.0361).
Figure 2

(A) Immunoblot showing the expression of MICL and PI3K-p85 over time with and without MSU (1 mg/ml) treatment. Time points are represented as 20 minutes.

(B) Bar graph illustrating the densitometric ratio of MICL-P13K-p85 over time with and without MSU (1 mg/ml) treatment. The p-value is **p=0.0085.

(C) Western blot analysis showing the expression of MICL over time with MSU incubation. The blot includes lanes for different time points: 0, 10, 20, 30 minutes of MSU incubation in both pellet and supernatant fractions.
Figure 3

(A) Surface expression (MFI x % + cells) for Undifferentiated PLB-985 and Dibutyryl cAMP-differentiated PLB-985.

(B) MICL plasma membrane expression (MFI) for siCtrl and siMICL, with *p=0.021.

(C) IL-8 (pg/ml) for siCtrl and siMICL, with *p=0.0464.

(D) IL-8 (pg/ml) for IgG2a and 50c1 with *p=0.048.
Figure 4

**IL-1β (pg/ml)**

- MSU (1mg/ml)
- IgG2a (2μg/ml)
- 50C1 (2μg/ml)
- TNF (250U/ml)

|          | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
|----------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSU (1mg/ml) |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| IgG2a (2μg/ml) |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| 50C1 (2μg/ml)   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| TNF (250U/ml)    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

Figure 4
Figure 6

Panel A: Graph showing the change in nmol Ca^2+ with time (seconds) after the addition of MSU. The graph compares the response of 50c1 and IgG2a.

Panel B: Bar graph showing MSU-induced calcium mobilization (area under the curve) for IgG2a and 50c1. The asterisk indicates a statistical significance level of p=0.0176.
Figure 7

A

MICL Surface Expression (Ratio of Control)

*** p = 0.0002

MSU (1mg/ml)  
-  -  +  +

Colchicine (10µM)  
-  +  -  +

B

MICL Surface Expression (Ratio of Control)

ns

Colchicine (10µM)  
-  +  -  +

50C1 (2µg/ml)  
-  -  +  +
Figure 8

![Graph showing IL-8 pg/ml levels with Colchicine and MSU treatments.](image)

- **IL-8 pg/ml**
  - 0
  - 50
  - 100
  - 150
  - 200

- **Colchicine (10μM)**
  - -
  - -
  - +
  - +

- **MSU (1mg/ml)**
  - -
  - +
  - -
  - +

* p = 0.0120